A Double Blind Clinical Trial of DCS for Food Anxiety

The Washington University

Status: Completed

Conditions: Anorexia and Bulimia Nervosa

Treatments: Drug: Setraline; Drug: Placebo vs Setraline

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT01996644

201212062

F31MH096433-01 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

This is a pilot study investigating if cycloserine (DCS; a learning enhancement medication) augments exposure therapy for food anxiety in patients with anorexia and bulimia nervosa. The investigators expect that (a) exposure therapy will reduce anxiety (b) anxiety will be reduced more in the DCS relative to placebo condition (c) participants in the DCS condition will have a greater increase in Body Mass Index.

Full description

This study investigated if DCS vs placebo augmented food exposure in individuals with eating disorders.

Enrollment: 47 patients

Sex: All

Ages: 14 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed with Anorexia Nervosa, Bulimia Nervosa, Eating Disorder Not Otherwise Specified

Exclusion criteria

• Pregnant or planning on becoming pregnant
• Psychotic or Manic

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

47 participants in 2 patient groups, including a placebo group

Setraline

Experimental group

Description:

250 mg DCS (setraline) versus placebo plus exposure

Treatment:

Drug: Setraline

placebo

Placebo Comparator group

Description:

Placebo group plus exposure

Treatment:

Drug: Placebo vs Setraline